**Supplementary Table 1:** ICD-10 codes used to categorize underlying cause of death for individuals diagnosed with hepatocellular carcinoma in New York City and reported to have died from 2001-2012.

Cause of death category	ICD-10 codes		
Hepatocellular carcinoma	C22, excluding C22.1		
Other liver disease	B16, B18.1, B17.1, B18.2, K70, K74		
Other cancer	C00-C97, excluding C22 except C22.1		
Cardiovascular disease	I00–I01, I05–I06, I09–I13, I21, I24–I28, I31, I33–35, I38, I40, I42, I44, I46, I48–I51, I60–I64, I67, I69–I74, I77–I78		
HIV/AIDS-associated	B20-B24		
Substance abuse-related	F11–F19, X40–X44		

**Supplementary Table 2**: Kaplan-Meier estimates of the survival probability among individuals with hepatocellular carcinoma and median survival time since hepatocellular carcinoma diagnosis, by stage and hepatitis infection status, New York City, 2001–2012.

	HBV mono- infection (n=1564)	HCV mono- infection (n=3330)	HBV/HCV coinfection (n=193)	Neither infection (n=3495)	Total (n=8582)
Overall	(== ====)	(-2-2222)	(, -, -, -, -, -, -, -, -, -, -, -, -	(42 2 1)	
Survival probability (%)					
1 month	91.7	89.7	91.7	82.4	86.9
6 months	67.8	65.4	65.1	52.6	60.5
12 months	58.4	52.2	53.8	38.8	47.9
60 months	37.5	20.0	29.5	16.1	22.0
Median survival time after HCC diagnosis, months (95% CI) Local Stage	22.3 (17.7-26.3)	13.1 (12.2-14.5)	14.9 (9.9-22.9)	6.9 (6.3-7.5)	10.9 (10.3-11.5)
Survival probability (%)					
1 month	96.2	95	94.8	88.7	93.1
6 months	86.4	81.3	86.4	69.2	78.2
12 months	79.6	70.4	74.1	58.8	68.3
60 months	55.8	30.5	47.8	27.1	34.9
Median survival time after HCC diagnosis, months (95% CI) Regional Stage	94.5 (68.5-undef)	28.1 (24.7-31.4)	42.7 (31.9-97.1)	8.4 (7.4-9.8)	29.1 (27.3-31.7)
Survival probability (%)					
1 month	91.9	88.8	86.8	85.7	88.1
6 months	60.1	56.8	36.8	52.3	55.2
12 months	50.5	42.3	25.7	36.6	41.2
60 months	29.4	14.3	15.6	14.6	17.2
Median survival time after HCC diagnosis, months (95% CI) Distant Stage	12.5 (8.1-16.5)	8.4 (7.4-9.8)	4.7 (3.0-8.7)	6.9 (5.8-8.1)	8.0 (7.3-8.9)
G					
Survival probability (%) 1 month	2.5		<b>-</b>		
6 months	82.9	76.4	78.6	74.4	77
6 months	39.1	35.9	35.7	29.6	33.7
60 months	26.4	17.9	17.9	15.6	18.7
Median survival time	14.9	4.0	3.6	5.0	6.9
after HCC diagnosis, months (95% CI)	3.7 (3.1-4.8)	3.2 (2.7-4.0)	3.1 (1.6-8.7)	2.6 (2.3-3.0)	3.0 (2.7-3.3)

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma.

**Supplementary Table 3:** Hazard ratios comparing the risk of death since time of hepatocellular carcinoma diagnosis by hepatitis infection status, compared with neither infection, New York City, 2001–2012.

	aHR <sup>a</sup>	95% CI	
HBV mono-infection	0.81	0.73-0.8	9
HCV mono-infection <sup>b</sup>			
6 month follow-up	0.95	0.90-1.0	2
1 year follow-up	1.06	0.98-1.1	4
5 year follow-up	1.34	1.20-1.5	1
HBV/HCV coinfection	0.96	0.79-1.1	7

Abbreviations: aHR, adjusted hazards ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.

<sup>&</sup>lt;sup>a</sup> Hazard ratios are adjusted for age at hepatocellular carcinoma diagnosis, race/ethnicity, sex, neighborhood poverty level, cancer stage at diagnosis, and year of hepatocellular carcinoma diagnosis.

<sup>&</sup>lt;sup>b</sup> A significant interaction between HCV infection status and time was observed, indicating a violation of the proportional hazards assumption. Hazard ratios for HCV are therefore calculated at different follow-up times to account for the changing hazards over time.